A number of research firms have changed their ratings and price targets for ADARx Pharmaceuticals (NASDAQ: ADRX):
- 10/21/2026 – ADARx Pharmaceuticals was upgraded by Zacks Research to “hold”.
- 10/20/2026 – ADARx Pharmaceuticals is now covered by TD Cowen. They set a “buy” rating on the stock.
- 10/20/2026 – ADARx Pharmaceuticals is now covered by UBS Group. They set a “buy” rating and a $35.00 price target on the stock.
- 10/20/2026 – ADARx Pharmaceuticals is now covered by Morgan Stanley. They set an “overweight” rating and a $32.00 price target on the stock.
- 10/20/2026 – ADARx Pharmaceuticals is now covered by UBS Group. They set a “buy” rating and a $35.00 price target on the stock.
- 10/20/2026 – ADARx Pharmaceuticals is now covered by JPMorgan Chase & Co.. They set an “overweight” rating and a $38.00 price target on the stock.
- 10/3/2026 – ADARx Pharmaceuticals was upgraded by Wall Street Zen to “hold”.
ADARx Pharmaceuticals Price Performance
Shares of NASDAQ:ADRX traded down $1.96 during midday trading on Thursday, hitting $13.00. The stock had a trading volume of 466,268 shares, compared to its average volume of 540,630. ADARx Pharmaceuticals, Inc. has a 12 month low of $12.75 and a 12 month high of $23.21.
Insider Buying and Selling at ADARx Pharmaceuticals
In other news, Director Simeon George acquired 1,600,000 shares of the firm’s stock in a transaction dated Monday, September 28th. The stock was bought at an average price of $17.00 per share, with a total value of $27,200,000.00. Following the transaction, the director directly owned 5,554,094 shares in the company, valued at approximately $94,419,598. The trade was a 40.46% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, major shareholder Sr One Capital Management, Llc acquired 1,600,000 shares of the stock in a transaction dated Monday, September 28th. The shares were purchased at an average price of $17.00 per share, for a total transaction of $27,200,000.00. Following the completion of the purchase, the insider directly owned 5,554,094 shares in the company, valued at $94,419,598. The trade was a 40.46% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders bought a total of 3,261,516 shares of company stock worth $55,445,772 over the last quarter.
ADARx Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing medicines that target disease-driving proteins through RNA-based technologies. The company’s platform is designed to support potent and durable control of protein production, with the goal of creating therapies that may be administered less frequently than conventional treatments.
ADARx is advancing a pipeline of investigational therapeutics for conditions involving the kallikrein-kinin and complement pathways, which are implicated in hereditary angioedema and other immune-mediated or inflammatory diseases.
Read More
- Five stocks we like better than ADARx Pharmaceuticals
- Could the Midterms Revive Medicare for All? 3 Healthcare Stocks to Watch
- Qualcomm Beat Earnings, But Its Fastest-Growing Businesses Have a Catch
- Oil, Uranium, or Renewables? 3 Energy Plays for a Changing Market
- South Korea’s Chip Exports Are Soaring—So Why Is This ETF Down 20%?
Receive News & Ratings for ADARx Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADARx Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.
